3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Brain Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pain, Postoperative
2
Pain
2
Ovarian Neoplasms
2
Neoplasms
2
Warts
1
Stroke
1
Sepsis
1
Schwannomatosis
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroinflammatory Diseases
1
Neurilemmoma
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypoxia
1
Hyperthermia
1
Hemorrhage
1
Glycopyrrolate
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Interventions
Bevacizumab
35
Paclitaxel
31
Carboplatin
24
pembrolizumab
23
Specimen Handling
21
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
olaparib
16
liposomal doxorubicin
16
Cyclophosphamide
15
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Disulfides
8
Doxorubicin
7
aldesleukin
6
Surveys and Questionnaires
6
palbociclib
5
Oxaliplatin
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
X-Rays
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Saline Solution
×
90 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts
NCT06888921
2026-04-01
MAIA-ovarian
Compugen Ltd
Phase 1/2
Recruiting
60 enrolled